Neuromuscular RX for Genetic Diseases: 90.9% of denials overturned
In 11 California IMR decisions from 2019 to 2025, reviewers overturned 10 (90.9%). In the last five years: 87.5% of 8. 9 were medical-necessity disputes, 2 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 3 | 66.7% |
| 2022 | 2 | 100.0% |
| 2023 | 2 | 100.0% |
| 2025 | 1 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 4 | 100.0% | 90.9% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient’s parent has requested authorization and coverage for Duvyzat suspension.The U.S. Food and Drug Administration (FDA) has approved Duvyzat for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. Importantly, the FDA approval for Duvyzat is not mutation-specific and is indicated for all …”
“Nature of Statutory Criteria/Case Summary: The patient’s parent has requested authorization and coverage for Spinraza (nusinersen). The current medical literature and guideline support treatment for all symptomatic patients with spinal muscular atrophy (SMA) above two years of age with either Spinraza or Evrysdi. However, there is a lack of clinical trials showing the superiority of either Spinraza or Evrysdi. Thus, …”
“The physician reviewer found that An enrollee has requested authorization and coverage for the medication Emflaza 30 mg tablet.The submitted documentation supports that the requested medication is medically necessary. Muscular dystrophy refers to a genetic disease characterized by a progressive myopathic process. Duchenne Muscular Dystrophy (DMD) is secondary to mutations of the dystrophin gene. Weakness is the principal symptom of …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Evrysdi. Spinal muscular atrophy (SMA) is an autosomal recessive, inherited genetic disease characterized by degeneration of alpha motor neurons in the spinal cord. Several innovative medications have recently been developed that improve or ameliorate symptoms in many patients. In 2020, the U.S. Food and Drug Administration (FDA) …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Neuromuscular RX denials for Genetic Diseases overturned?
In 11 California IMR decisions from 2019 to 2025, reviewers overturned 10 (90.9%). In the last five years: 87.5% of 8. 9 were medical-necessity disputes, 2 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.